FindTrial
Sign In

tendency of vomiting with two different drugs who undergo breast surgery.

Effects of sugammadex versus neostigmine on postoperative nausea and vomiting after general anesthesia in patients undergoing breast surgery : A Randomized Clinical Trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/060300
Enrollment
84
Registered
2023-11-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Sugammadex: effect of nausea and vomiting will be seen after sugammadex 2mg per kg till 12 hours post operative. Control Intervention1: Neostgimine: Effect of nausea and vomiting after

Sponsors

Dr Bibha Kumari
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to participate. 2.Patients 18-70 years of age. 3.ASA grade 1-4 patients. 4.Breast surgery requiring General Anaesthesia.

Exclusion criteria

Exclusion criteria: 1.Patients with history of PONV 2.Impaired renal function 3.Requiring postoperative ventilation 4.Allergic to any study drugs

Design outcomes

Primary

MeasureTime frame
To evaluate the incidence of PONV in patients undergoing reversal with sugammadex versus Neostigmine after general anaesthesia in breast surgery. Timepoint: 8 months.—

Secondary

MeasureTime frame
To asses the postoperative need of anti-emetics and respiratory complications i.e. laryngospasm, bronchospasm & sore throat.Timepoint: 8 months—

Countries

India

Contacts

Public ContactDr Sarthak Misra

Indira Gandhi institute of medical sciences

drsarthakmisra2021@gmail.com8210641979

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026